Patents by Inventor Mark Gelfand

Mark Gelfand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170348050
    Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.
    Type: Application
    Filed: June 15, 2017
    Publication date: December 7, 2017
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Howard R. Levin, Mark Gelfand, Nicolas Zadno
  • Publication number: 20170326363
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 16, 2017
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: MARK E. DEEM, HANSON GIFFORD, III, DENISE ZARINS, DOUGLAS SUTTON, ERIK THAI, MARK GELFAND, HOWARD R. LEVIN
  • Publication number: 20170326359
    Abstract: The present invention is related to an implantable medical device for treating breathing disorders and cardiac disorders by delivering stimulation energy to the phrenic nerve, hypoglossal nerves and cardiac muscle tissues.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 16, 2017
    Inventors: Mark Gelfand, Howard R. Levin
  • Patent number: 9814873
    Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: November 14, 2017
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 9808303
    Abstract: Methods and cryogenic devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation. Some methods include advancing a cryo-ablation catheter into a patient's vasculature and ablating tissue within a carotid septum.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: November 7, 2017
    Assignee: Cibiem, Inc.
    Inventors: Eric Ryba, Mark Gelfand
  • Publication number: 20170291032
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Application
    Filed: June 21, 2017
    Publication date: October 12, 2017
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20170274190
    Abstract: A method and apparatus for treatment of heart failure by increasing secretion of endogenous naturetic hormones ANP and BNP such as by stimulation of the heart atria. Heart pacing is done at an atrial contraction rate that is increased and can be higher than the ventricular contraction rate. Pacing may include mechanical distension of the right atrial appendage. An implantable device is used to periodically cyclically stretch the walls of the appendage with an implanted balloon.
    Type: Application
    Filed: June 5, 2017
    Publication date: September 28, 2017
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20170265937
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Application
    Filed: March 31, 2017
    Publication date: September 21, 2017
    Inventors: Howard R. Levin, Mark Gelfand
  • Patent number: 9757180
    Abstract: Systems, devices, and methods for treating a patient having a sympathetically mediated disease associated at least in part with augmented peripheral chemoreflex or heightened sympathetic activation. The treatments include ablating one or more peripheral chemoreceptors or associated afferent nerves to reduce or remove afferent neural signals from the peripheral chemoreceptor.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: September 12, 2017
    Assignee: Cibiem, Inc.
    Inventors: Mark Gelfand, Howard Levin, Charles Lennox
  • Patent number: 9757192
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: September 12, 2017
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Howard R. Levin, Mark Gelfand
  • Publication number: 20170245926
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: March 22, 2017
    Publication date: August 31, 2017
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20170245925
    Abstract: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.
    Type: Application
    Filed: March 14, 2017
    Publication date: August 31, 2017
    Inventors: Neil Barman, Howard Levin, Paul Sobotka, Mark Gelfand
  • Patent number: 9744351
    Abstract: The present invention is related to an implantable medical device for treating breathing disorders and cardiac disorders by delivering stimulation energy to the phrenic nerve, hypoglossal nerves and cardiac muscle tissues.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: August 29, 2017
    Assignee: Respicardia, Inc.
    Inventors: Mark Gelfand, Howard R. Levin
  • Patent number: 9743983
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: August 29, 2017
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Howard R. Levin, Mark Gelfand
  • Publication number: 20170239480
    Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: October 3, 2016
    Publication date: August 24, 2017
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20170232275
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: October 3, 2016
    Publication date: August 17, 2017
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 9731136
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: August 15, 2017
    Assignee: BackBeat Medical, Inc.
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 9731132
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: August 15, 2017
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark Deem, Denise Zarins, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark
  • Publication number: 20170202617
    Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues. In some embodiments, thermally-induced renal neuromodulation is achieved via delivery of a pulsed thermal therapy.
    Type: Application
    Filed: April 3, 2017
    Publication date: July 20, 2017
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Andrew Wu, Hanson Gifford, III, Mark Deem, Mark Gelfand, Howard R. Levin
  • Patent number: 9707035
    Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: July 18, 2017
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Howard R. Levin, Mark Gelfand, Nicolas Zadno